Added to YB: 2025-07-31
Pitch date: 2025-07-30
ATYR [bearish]
aTyr Pharma, Inc.
+85.03%
current return
Author Info
AnthonyStaj shares thoughts and musings on biotech, mostly. L/S, not afraid of indication, highly focused on clinical and commercial analysis. Sign up for the newsletter.
Company Info
aTyr Pharma, Inc., a clinical stage biotechnology company, engages in the discovery and development of product candidates that translate tRNA synthetase biology into new therapies for fibrosis and inflammation in the United States.
Market Cap
$73.8M
Pitch Price
$4.90
Price Target
1.00 (+29%)
Dividend
N/A
EV/EBITDA
0.06
P/E
-0.89
EV/Sales
-22.27
Sector
Biotechnology
Category
N/A
ATYR: A platform in search of an indication
ATYR short: Efzofitimod for pulmonary sarcoidosis lacks compelling evidence. Ph1/2 data shows minimal steroid reduction (1.8mg/d) vs placebo & baseline imbalances favoring treatment arms. WHEP domain's CCR5 chemotactic activity contradicts anti-inflammatory MoA. Ph3 needs ~2-3mg/d OCS reduction in milder population to hit p<0.025.
Read full article (24 min)